How I treat non-transfusion-dependent β-thalassemia

dc.contributor.authorSaliba, Antoine N.
dc.contributor.authorMusallam, Khaled M.
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:46:05Z
dc.date.available2025-01-24T11:46:05Z
dc.date.issued2023
dc.description.abstractThe intricate interplay of anemia and iron overload under the pathophysiological umbrella of ineffective erythropoiesis in non-transfusion-dependent β-thalassemia (NTDT) results in a complex variety of clinical phenotypes that are challenging to diagnose and manage. In this article, we use a clinical framework rooted in pathophysiology to present 4 common scenarios of patients with NTDT. Starting from practical considerations in the diagnosis of NTDT, we delineate our strategy for the longitudinal care of patients who exhibit different constellations of symptoms and complications. We highlight the use of transfusion therapy and novel agents, such as luspatercept, in the patient with anemia-related complications. We also describe our approach to chelation therapy in the patient with iron overload. Although tackling every specific complication of NTDT is beyond the scope of this article, we touch on the management of the various morbidities and multisystem manifestations of the disease. © 2023 The American Society of Hematology
dc.identifier.doihttps://doi.org/10.1182/blood.2023020683
dc.identifier.eid2-s2.0-85168016171
dc.identifier.pmid37478396
dc.identifier.urihttp://hdl.handle.net/10938/30628
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofBlood
dc.sourceScopus
dc.subjectBeta-thalassemia
dc.subjectChelation therapy
dc.subjectHumans
dc.subjectIron chelating agents
dc.subjectIron overload
dc.subjectThalassemia
dc.subjectAcetylsalicylic acid
dc.subjectAlanine aminotransferase
dc.subjectAmbrisentan
dc.subjectAntibiotic agent
dc.subjectAnticoagulant agent
dc.subjectAntithrombocytic agent
dc.subjectBeta adrenergic receptor blocking agent
dc.subjectBilirubin
dc.subjectBisphosphonic acid derivative
dc.subjectBosentan
dc.subjectCalcium channel blocking agent
dc.subjectDeferasirox
dc.subjectDeferiprone
dc.subjectDeferoxamine
dc.subjectDexamethasone
dc.subjectDipeptidyl carboxypeptidase inhibitor
dc.subjectFerritin
dc.subjectFerrous sulfate
dc.subjectGlecaprevir plus pibrentasvir
dc.subjectHaptoglobin
dc.subjectHemoglobin
dc.subjectHemoglobin a2
dc.subjectHemoglobin alpha chain
dc.subjectHepatitis vaccine
dc.subjectHydroxyurea
dc.subjectInfluenza vaccine
dc.subjectIron
dc.subjectIron chelating agent
dc.subjectLactate dehydrogenase
dc.subjectLedipasvir plus sofosbuvir
dc.subjectLevothyroxine
dc.subjectLow molecular weight heparin
dc.subjectLuspatercept
dc.subjectMacitentan
dc.subjectPentoxifylline
dc.subjectPneumococcus vaccine
dc.subjectRiociguat
dc.subjectRuxolitinib
dc.subjectSildenafil
dc.subjectSodium nitrite
dc.subjectSofosbuvir plus velpatasvir
dc.subjectTadalafil
dc.subjectAdult
dc.subjectAnalgesia
dc.subjectAnemia
dc.subjectAntibiotic therapy
dc.subjectAnticoagulant therapy
dc.subjectAntiviral therapy
dc.subjectBeta thalassemia
dc.subjectBlood transfusion
dc.subjectCase report
dc.subjectCerebrovascular accident
dc.subjectClinical article
dc.subjectDrug dose titration
dc.subjectDual energy x ray absorptiometry
dc.subjectEndocrine bone disease
dc.subjectErythrocyte transfusion
dc.subjectExertional dyspnea
dc.subjectExtramedullary hematopoiesis
dc.subjectFatigue
dc.subjectFemale
dc.subjectFerritin blood level
dc.subjectFunctional status
dc.subjectGallstone
dc.subjectGene insertion
dc.subjectGenotype
dc.subjectHeart left ventricle ejection fraction
dc.subjectHemoglobin determination
dc.subjectHepatitis a
dc.subjectHepatitis b
dc.subjectHepatitis c
dc.subjectHepatosplenomegaly
dc.subjectHuman
dc.subjectHypothyroidism
dc.subjectIron deficiency anemia
dc.subjectKnee pain
dc.subjectLeg pain
dc.subjectLeg ulcer
dc.subjectLiver cell carcinoma
dc.subjectLiver cirrhosis
dc.subjectLiver fibrosis
dc.subjectLow back pain
dc.subjectLung artery pressure
dc.subjectMale
dc.subjectMean corpuscular hemoglobin concentration
dc.subjectMean corpuscular volume
dc.subjectMicrocytic anemia
dc.subjectMorbidity
dc.subjectMultiple cycle treatment
dc.subjectNon transfusion dependent thalassemia
dc.subjectNuclear magnetic resonance imaging
dc.subjectOsteopenia
dc.subjectPathophysiology
dc.subjectPatient care
dc.subjectPatient referral
dc.subjectPhase 2 clinical trial (topic)
dc.subjectPhenotype
dc.subjectPlatelet count
dc.subjectPregnancy
dc.subjectProtein electrophoresis
dc.subjectPseudotumor
dc.subjectPulmonary hypertension
dc.subjectRandomized controlled trial (topic)
dc.subjectReticulocyte count
dc.subjectReview
dc.subjectSymptom
dc.subjectSyndrome delineation
dc.subjectThalassemia intermedia
dc.subjectThrombosis
dc.subjectTransthoracic echocardiography
dc.subjectTreatment indication
dc.subjectTreatment refusal
dc.subjectTricuspid regurgitation velocity
dc.subjectUlcer healing
dc.titleHow I treat non-transfusion-dependent β-thalassemia
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2023-570.pdf
Size:
2 MB
Format:
Adobe Portable Document Format